[1]日本透析医学会.わが国の慢性透析疗法の现状.[J].https://docs.jsdt.or.jp/overview/file/2020/pdf/02.pdf, , :-
[2]Pathak A, Lebrin M, Vaccaro A, et al.Pharmacology of levosimendan: inotropic,vasodilatory and cardioprotective effects[J].J Clin Pharm Ther, 2013, 38(5):341-349
[3]Gong B, Li Z, Yat Wong PC.Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis[J].J Cardiothorac Vasc Anesth, 2015, 29(6):1415-1425
[4]Long YX, Cui DY, Kuang X, et al.Effect of levosimendan on renal function in background of left ventricular dysfunction: a meta-analysis of randomized trials[J].Expert Opin Drug Saf, 2021, 20(11):1411-1420
[5]Bove T, Matteazzi A, Belletti A, et al.Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials[J].Heart Lung Vessel, 2015, 7(1):35-46
[6]Patel PH, Nguyen M, Rodriguez R, et al.A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management[J].Cureus, 2021, 13(1):e12419-
[7]Teerlink JR, Felker GM, McMurray JJ, et al.Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study[J].J Am Coll Cardiol, 2016, 67(12):1444-1455
[8]Teerlink JR, Diaz R, Felker GM, et al.Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure[J].N Engl J Med, 2021, 384(2):105-116
[9]Teerlink JR, Felker GM, McMurray JJ, et al.Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial[J].Lancet, , 388:2895–2903., 2016, 388(10062):2895-2903
[10]Francis GS, Bartos JA, Adatya S.Inotropes[J].J Am Coll Cardiol, 2014, 63(20):2069-2078
[11]Chong LYZ, Satya K, Kim B, et al.Milrinone Dosing and a Culture of Caution in Clinical Practice[J].Cardiol Rev, 2018, 26(1):35-42
[12]Liao X, Qian L, Zhang S, et al.Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock[J].J Healthc Eng, 2020, 2020:8862256-
[13]Cuffe MS, Califf RM, Adams KF Jr, et al.Short-term intravenous milrinone for acute exacerbation of chronic heart failure[J].JAMA, 2002, 287: 1541–1547., 2002, 287(12):1541-1547
[14]Klein L, Massie BM, Leimberger JD, et al.Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF)[J].Circ Heart Fail, 2008, 1(1):25-33
[15]Ziff OJ, Kotecha D.Digoxin: The good and the bad[J].Trends Cardiovasc Med, 2016, 26(7):585-595
[16]Hood WB Jr, Dans AL, Guyatt GH, et al.Digitalis for treatment of heart failure in patients in sinus rhythm[J].Cochrane Database Syst Rev, 2014, 2014(4):C-D002901
[17]Digitalis Investigation Group.The effect of digoxin on mortality and morbidity in patients with heart failure[J].N Engl J Med, 1997, 336(8):525-533
[18]Ziff OJ, Lane DA, Samra M, et al.Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data[J].BMJ, 2015, 351:h4451., 2015, 351:h4451-
[19]Testani JM, Brisco MA, Tang WH, et al.Potential effects of digoxin on long-term renal and clinical outcomes in chronic heart failure[J].J Card Fail, 2013, 19(5):295-302
[20]Sonnenblick EH, Frishman WH, LeJemtel TH.Dobutamine: a new synthetic cardioactive sympathetic amine[J].N Engl J Med, 1979, 300(1):17-22
[21]Lannemyr L, Ricksten SE, Rundqvist B, et al.Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double-Blind Controlled Trial[J].J Am Heart Assoc, 2018, 7(16):e008455-
[22]Mathew R, Di Santo P, Jung RG, et al.Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock[J].N Engl J Med, 2021, 385(6):516-525
[23]Russell JA.Vasopressor therapy in critically ill patients with shock[J].Intensive Care Med, 2019, 45(11):1503-1517
[24]Levy B, Klein T, Kimmoun A.Vasopressor use in cardiogenic shock[J].Curr Opin Crit Care, 2020, 26(4):411-416
[25]Léopold V, Gayat E, Pirracchio R, et al.Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients[J].Intensive Care Med, 2018, 44(6):847-856
[26]Backer DD, Biston P, Devriendt J, et al.Comparison of dopamine and norepinephrine in the treatment of shock[J].N Engl J Med, 2010, 362(9):779-789
[27]Jaguszewski MJ, Gasecka A, Targonski R, et al.Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis[J].Cardiol J, 2021, 28(3):492-493
[28]Mathew R, Visintini SM, Ramirez FD, et al, Labinaz M, Hibbert BM.Efficacy of milrinone and dobutamine in low cardiac output states: Systematic review and meta-analysis[J].Clin Invest Med, 2019, 42(2):E26-32
